You are here: Industry Insights > Market News > Bring it on, pharma: Finger-pointing at insurers provokes AHIP tweetstorm

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

PVP-K30-----pharma excipients(CAS No.9003-39-8)

Tobramycin

Povidone iodine 20% powder

Povidone iodine 10% powder

SULBACTAM SODIUM STERILE

Food Additives Bulk Sucralose Neotame Advantame Powder

Bring it on, pharma: Finger-pointing at insurers provokes AHIP tweetstorm

fiercepharmaSeptember 29, 2017

Tag: AHIP , insurers , pharma

Favorites

Call it unintended-but-predictable consequences: Launched this summer, a pharma industry campaign called "Let's Talk About Cost" highlights the role of insurers and middlemen in drug spending. Now, top insurers are talking back, with no punches pulled.

America's Health Insurance Plans, the insurance industry's lobby group, called out pharma on Twitter in a series of posts about drug expenses, misuse of drug laws, price hikes, patent deals and more. It isn't the first time the industries have sparred and won't be the last.

Previous:Lilly steps up to rival Pfizer, Novartis with Verzenio breast cancer approval

Next:Iconic Landmarks Turn Red for World Heart Day: Friday 29 September 2017

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China

PharmaSourcesSeptember 19, 2024

InnoCare Pharma announced today the approval of the Investigational New Drug (IND) to conduct the clinical trial of B-cell lymphoma-2 (BCL2) inhibitor ICP-248 in combination with azacitidine for acute myeloid leukemia (AML) in China.

Cordlife Unveils Enhanced Processing and Storage Facility in Singapore; Strengthens Processes as It Resumes Collection of Cord Blood Units in a Controlled Manner

PharmaSourcesSeptember 18, 2024

Latest Data of InnoCare’s Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2024

PharmaSourcesSeptember 14, 2024

Bring it on, pharma: Finger-pointing at insurers provokes AHIP tweetstorm | Pharmasources.com

Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study

Biotech NewswireAugust 28, 2024

Currax Pharmaceuticals LLC announced the results of a Cardiovascular Health Outcomes Analysis.The results showed there is no evidence of excess cardiovascular risk.

You may like
More>>

Pramlintide acetate supplier API Pharmaceutical Polypeptide made in china

Pharmaceutical Biotechnology Engineering

BFS leak tester in pharmaceutical

Anastrozole usp standard pharma grade made in China

Entecavir 99%min Pharmaceutical Nucleoside Antivirus products made in china

Multifunctional Pharmaceutical High Purity CBD Extraction Production Units Hemp Extraction Tank

Pharma Grade Artemisinin

Pharmaceutical Grade API Levosimendan CAS 141505-33-1

Ramosetron Hydrochloride other active pharmaceutical ingredients

Carbetocin supplier Pharmaceutical API Polypeptide made in china

Bring it on, pharma: Finger-pointing at insurers provokes AHIP tweetstorm

Related News

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China

Cordlife Unveils Enhanced Processing and Storage Facility in Singapore; Strengthens Processes as It Resumes Collection of Cord Blood Units in a Controlled Manner

Latest Data of InnoCare’s Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2024

Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study

You may likeMore>>

You may like
More>>